The Institute of Cancer Research, London

New Capabilities

Trial collaborator and presenter of Cohort 5 results

The U.S. Food and Drug Administration granted accelerated approval on November 6 to RYBREVANT FASPRO, the subcutaneous form of amivantamab, for advanced head and neck cancer. The decision follows a 77% confirmed response rate for a first-line combination of amivantamab, pembrolizumab and carboplatin in 22 patients with HPV-unrelated recurrent or metastatic head and neck squamous cell carcinoma, reported at ESMO 2026.

Updated 2 days ago